An appropriate dosing strategy would need to be developed to evaluate an approach where a Glut1 inhibitor could impair tumor growth and metabolism without overly impeding type 1 conventional DC (cDC1) and TIL function. The gene discussed is SLC2A1; the disease is neoplasm.